The development programs of the company include radiotherapeutic, radioimmunotherapeutic and immunotherapeutic products for treatment of various solid cancers. The companys’s lead candiate Radspherin is currently developed for two indications, peritoneal carcinomatosis from ovarian cancer and from colorectal cancer, but are also relevant for treating other types of cancers. 

The company has developed proprietary antibodies. The antibodies are used as targeting modules of the immune-and radioimmunotherapeutic candidates and are currently in a discovery phase. Oncoinvent has a strategy to be a multiple compound company and will continue to focus on developing new product candidates.

Anders Månsson

Chief Executive Officer


Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.